The Editorial Executive Committee welcomes letters, which should be less than 250 words. Before a decision to publish is made, letters which refer to a published article may be sent to the author for a response. Any letter may be sent to an expert for comment. When letters are published, they are usually accompanied in the same issue by their responses or comments. The Committee screens out discourteous, inaccurate or libellous statements. The letters are sub-edited before publication. Authors are required to declare any conflicts of interest. The Committee's decision on publication is final.
Letter to the Editor
Editor, – The excellent editorial, 'Quality use of generic medicines' (Aust Prescr 2004;27:80-1) states 'confusion could be greatly reduced if generic names of the drugs were required to be more prominent [my emphasis] on the label than the 'brand' names'.
Recently, I was called to an elderly lady who had collapsed and was unable to get up from the floor. She was severely hypotensive because she had taken a double dose of enalapril, one that I had prescribed for her and one with a different brand name, prescribed by a locum doctor.
This is such an obvious danger that it needs to be confronted before more severe accidents and deaths occur.
How can the labelling requirement suggested in the Australian Prescriber editorial be brought about?